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Despite the major advancements in 
  cardiovascular medicine over the past 
50 years, heart disease and stroke remain 
the number one public health concern 
and primary causes of death today. The 
development of effective medicines that 
control blood pressure and cholesterol has 
significantly cut deaths from heart disease. 
According to a 2008 report, death rates for 
cardiovascular disease fell a remarkable 
26.4% between 1999 and 2005. Nonetheless, 
45% of Americans still have hypertension, 
high cholesterol or diabetes. According to 
a 2006 American Heart Association study 
cardiovascular disease accounted for over 
a third of all deaths in the United States. 
On average, every 40   seconds someone in 
the United States has a stroke. Heart dis-
ease and stroke are becoming a worldwide 
pandemic as developing nations are wit-
nessing the health burden. In developing 
nations approximately 14 million indi-
viduals died of cardiovascular disease in 
1990, and deaths are projected to rise to 
25 million by 2020.
What are the Grand Challenges that 
must be addressed to confront the obstacles 
for the creation of new medicines that will 
treat patients with cardiovascular disease? 
These Grand Challenges will be broken it 
into three broad categories:
1) Innovation;




Breakthroughs in elucidating the basic 
molecular pharmacology in cardiac/ vascular 
function, thrombosis/coagulation and lipid 
metabolism, has lead to significant advance-
ments in the current treatment paradigm 
for patients with heart disease. Innovation 
in these areas of research has lead to 
remarkable discoveries and significantly 
reduced the mortality and morbidity from 
  cardiovascular diseases. Notwithstanding, 
more work and a relentless pursuit of the 
basic science in cardiovascular biology is 
still needed.
Innovation is evident in the field of 
regenerative medicine. Regenerative medi-
cine is an emerging interdisciplinary field 
of scientific research and clinical applica-
tions that will impact significantly on the 
treatment of heart disease and diabetes. 
Research focused on the repair, replace-
ment, or regeneration of cardiac, vascular, 
or pancreatic tissues to restore function 
resulting from disease holds much prom-
ise. Cardiac regenerative medicine may 
use a combination of several technologi-
cal approaches including, but not limited 
to, the use of stem cells, soluble mole-
cules, genetic and tissue engineering, and 
advanced cell therapy. Promising clinical 
research is already available for the use of 
autologous bone marrow stem cells for 
the regeneration of ischemic heart muscle 
after myocardial infarction and cardiomy-
opathies. In addition to saving lives, such 
therapies will markedly reduce the cost 
of treating patients with heart failure. 
Moreover, regenerative medicine thera-
pies are relevant in the consideration of 
new therapeutic approaches for diabetes. 
Bone marrow stem cell transplantation or 
microencapsulated pancreatic islet cells 
using novel biomaterials could potentially 
provides a permanent solution and prevent 
the burden of diabetes.
Innovation is not solely found with small 
molecule compounds. Biopharmaceuticals 
have the opportunity to tackle previously 
intractable targets. The concept of vaccines 
to treat cardiovascular disease is now feasi-
ble. Moreover, medical device approaches 
such as drug eluting stents, implantable 
cardiac defibrillators, pacemakers, insulin 
pumps, and other devices will certainly have 
a place for new innovative approaches to 
treat cardiovascular disease and will con-
tinue to make an impact.
Innovation in the field of genetics and 
personalized medicine will be integrated 
into the discovery and development of 
new cardiovascular therapeutics. New 
genetic knowledge opens up the possibility 
of developing “targeted” therapies for peo-
ple with specific gene sequences, and it will 
help physicians choose from amongst exist-
ing medicines treatment that best meets an  
individuals genetic, lifestyle, and environ-
mental differences. In addition, research 
is evolving for the development of genetic 
tests that tells if patients are susceptible to 
certain types of disease.
translatIng BasIc research Into 
clInIcal realIty
Making new drugs is hard. Sometimes an 
obvious therapeutic target with excellent 
preclinical data does not translate into a 
safe and effective medicine. The recent 
example of the failure of the CETP inhibi-
tor Torcetrapib illustrates this problem. It 
was widely accepted that increasing HDL 
produces a beneficial therapeutic effect 
and decrease atherosclerosis. People were 
stunned when Torcetrapib failed to translate 
the biochemistry and pharmacology into a 
clinical benefit. Although the hypothesis 
that inhibition of CETP to increase HDL is 
still viable and compounds are still being 
developed, it cast doubt on the sole reliance 
of established biomarkers for the efficacy of 
potential new drugs.
The vasopeptidase inhibitor Omapatrilat 
is another example of how high-quality 
cardiovascular drug discovery and devel-
opment failed to produce an approvable 
medicine. Omapatrilat demonstrated excel-
lent antihypertensive efficacy in hyperten-
sive patients; however, there was a slightly 
higher incidence of severe angioedema 
than the standard of care ACE inhibitor. 
Omapatrilat was not approved because of 
these safety concerns. Transformational 
achievements from the past two decades 
for safe and effective antihypertensive Frontiers in Pharmacology | Cardiovascular and Smooth Muscle Pharmacology  September 2010  | Volume 1  |  Article 125  |  2
Ohlstein  Cardiovascular drug discovery and development
  laboratories. Academic laboratories and 
the biotech industry need to take on more 
responsibility for validating new targets and 
translating the science into commercially 
available medicines. In addition, the phar-
maceutical industry will be externalizing 
many discovery activities in order to access 
new discoveries and exploit the power of 
early stage innovative technologies.
Academia and the biotech industry need 
to create new partnerships with the phar-
maceutical industry for the resources and 
expertise that are essential for the clinical tri-
als and the overall drug development proc-
ess. The science is too complex, and the risks 
are too high. Companies will increasingly 
build alliances to bring novel therapeutic 
agents to the market. New models of part-
nerships between academia and the biotech 
industry, and the pharmaceutical industry 
will be critical to advance the new discover-
ies into new cardiovascular medicines.
conclusIons
The challenge in the advancement of new 
cardiovascular therapeutics goes beyond 
scientific breakthroughs and innovation. 
Issues involving patient access to medical 
care, smoking, physical activity, strategies 
to combat obesity, malnutrition, risk factor 
modification, regulatory, and public health 
policies that enable economic development 
of new cardiovascular medicines must be 
addressed before the benefits of new sci-
entific discoveries will be fully realized. 
Although the burden of cardiovascular dis-
ease is already emerging in developing coun-
tries, there exists a window of opportunity 
to prevent the pandemic from reaching its 
full potential magnitude. If the challenges of 
Innovation, Translation, and Commitment 
are addressed, we may be successful in pre-
venting cardiovascular disease from becom-
ing the number one global health burden.
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  attrition during drug development. Quick 
identification of those drugs that will not 
have successful target validation or those 
drugs that will not have sufficient safety is 
a critical element of modern drug discovery 
strategies. To make this process more effi-
cient, and to prevent unexpected safety issues 
late in the development process, scientists are 
seeking new methods to predict toxic effects 
early in the discovery process. Alternatives 
to traditional animal toxicology testing are 
being integrated into the early discovery and 
development process. Predictive toxicology 
is now one of the first steps in early drug 
discovery. In silico and in vitro technological 
methods are being used to predict in vivo 
results, thus a company can cost effectively 
develop drugs that will increase the prob-
ability of making it to the market.
commItment
Drug discovery and development in car-
diovascular disease has previously been 
sponsored by large investments by the 
pharmaceutical industry. We are witnessing 
a change in this paradigm. As a consequence 
of the successes in cardiovascular medicine 
over the past decade many pharmaceuti-
cal companies are shifting their focus and 
resources into different therapeutic areas. 
The incentive to develop cardiovascular 
agents has been reduced by increasing 
clinical development costs coupled with 
an augmented risk of failure due to the 
unprecedented nature of the promising 
drug targets and an increasingly challeng-
ing regulatory environment. In addition, 
the global recession and fundamental 
concerns about the lack of R&D produc-
tivity have resulted in substantial industry 
layoffs over the past 2 years. Furthermore, 
academic granting agencies have made a 
similar shift in funding into different ther-
apeutic areas. Consequently there are less 
scientists employed doing cardiovascular-
directed research today.
We are reaching a peak in the develop-
ment pipeline of drugs for cardiovascular 
disease. Investment from the previous dec-
ade resulted in new potential medicines 
to treat cardiovascular disease; however, 
future investment in cardiovascular dis-
ease is uncertain. Where will new inno-
vation in cardiovascular medicine come 
from? New medicines for heart disease 
are still needed and most of the basic sci-
ence and   discovery will occur in academic 
medicines raised the bar in terms of safety. 
New drugs for most  cardiovascular diseases 
will need to be “squeaky-clean” for patient 
safety. Thus the hurdles for regulatory 
approval have been raised.
In today’s environment of less funding, 
less validated targets, greater regulatory 
hurdles and larger clinical studies, there will 
be less risk-taking for companies to develop 
new cardiovascular therapeutics. This is a 
“Grand Challenge” but we must ask how can 
this trend be reversed? In order to improve 
the successful translation of research the 
emphasis in early development should be 
on understanding the molecular underpin-
nings of disease and developing biomark-
ers for therapeutic relevance. The emerging 
technologies of genomics, proteomics, and 
metabolomics combined with physiological 
profiling and imaging modalities will pro-
vide valuable insight. Differential gene and 
protein expression in disease or following 
drug treatment will instill valuable insight 
into the disease process.
Research shows that cardiovascular dis-
ease has a signature of molecular biomark-
ers. Biomarker signatures may dictate how 
a patient might respond to treatment. This 
is a powerful tool that will detect certain 
diseases at their earliest stages before the 
onset of symptoms and when they are most 
treatable and preventable. Biomarkers rep-
resent the future of cardiovascular medi-
cine, in which disease diagnosis, treatment, 
monitoring and prevention will be guided 
by a continual readout of a patient’s molec-
ular composition. The employment of 
novel biomarker strategies in clinical trials 
should serve to mitigate clinical develop-
ment risk.
Increasingly, the administration of new 
medicines for cardiovascular disease will be 
guided by predictive evidence from genetic 
and other molecular tests. As stated above, 
the expectation of “personalized medi-
cine” is that these tests will reveal whether 
an individual is likely to respond well to a 
drug, or avoid toxic side effects. A targeted 
approach to treatment will ensure that each 
patient receives the right medicine at the 
right time. Since molecular diagnostic tests 
reveals a patient’s susceptibility to disease, 
they also guide preventive treatment before 
symptoms arise.
A common saying in the pharmaceuti-
cal industry is to “fail early.” Toxicity identi-
fied during clinical trials is a major cause of 